Loading, Please Wait...
Source: Mesa Laboratories, Inc. – August 6, 2019 4:05 PM ET
LAKEWOOD, Colo., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa”) today announced that it has commenced concurrent underwritten public offerings of 375,000 shares of its common stock and $150 million aggregate principal amount of its convertible senior notes due 2025 (the “notes”). In addition, Mesa expects to grant (a) the underwriters of the common stock offering a 30-day option to purchase up to 56,250 additional shares and (b) the underwriters of the notes offering a 13-day option to purchase up to $22.5 million aggregate principal amount of additional notes. The offerings are subject to market and other conditions, and there can be no assurance as to whether or when the offerings may be completed or as to the actual size or terms of the offerings. The offerings are not contingent upon each other.
The notes are expected to mature on August 15, 2025, unless earlier converted or repurchased. The notes will be convertible at the option of holders in certain circumstances and during certain periods into cash, common stock or a combination thereof, at Mesa’s election. The interest rate, conversion rate and other terms of the notes will be determined at the time of pricing of the notes offering.
Mesa intends to use the net proceeds from the offerings to continue its acquisition strategy and for general corporate purposes. Mesa has not entered into any agreements with respect to any acquisitions at this time.
Jefferies LLC and J.P. Morgan Securities LLC are acting as the representatives of the underwriters for the offerings. Evercore Group L.L.C. and Wells Fargo Securities, LLC are also acting as book runners on the common stock offering and the notes offering, respectively, and Janney Montgomery Scott LLC is acting as a lead manager on the common stock offering.
The common stock offering and the notes offering are being made pursuant to Mesa’s shelf registration statement (including a base prospectus) and separate preliminary prospectus supplements related to each offering (together with such base prospectus, each a “prospectus”), all of which Mesa filed or will file with the Securities and Exchange Commission. Before investing in Mesa’s common stock or notes, investors should read the prospectuses, including the documents incorporated by reference therein, and any free writing prospectus related to the common stock offering and the notes offering. These documents may be freely obtained by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-821-7388, or by email at Prospectus_Department@Jefferies.com, and from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at firstname.lastname@example.org.
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any offer or sale of, the shares or notes in any state or jurisdiction in which the offer, solicitation, or sale of the shares or notes would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.
About Mesa Laboratories, Inc.
Mesa Laboratories, Inc. designs, manufactures and markets quality control products and services. Mesa is headquartered in Lakewood, Colorado, and operates out of ten physical locations globally.
Cautionary Language Concerning Forward-Looking Statements
This press release contains forward-looking statements regarding our future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding the size of the proposed offerings, expectations with respect to granting the underwriters options to purchase additional shares or notes, completion of the proposed offerings, and the anticipated use of proceeds of the proposed offerings, constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, uncertainties related to market conditions and the completion of the offerings on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Mesa’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q on file with the Securities and Exchange Commission and the other reports that Mesa periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Mesa contemplated by these forward-looking statements. These forward-looking statements reflect management’s current views and Mesa does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.
Contact: Gary Owens, President and CEO John Sakys, CFO both of Mesa Laboratories, Inc. 303-987-8000